Genelex has been a leader in pharmacogenetic testing since 2000. Our high-complexity laboratory facilities feature robotic DNA extraction and testing, proprietary test platforms and methodologies, rapid-turnaround, and test validation across multiple platforms.
Studies have shown that incorporating genetic factor results from pharmacogenetic tests into the prescribing process can help improve efficacy and reduce adverse effects.
Tests can be ordered individually or as panels.
Clinically Actionable Pharmacogenetic Tests
Genelex currently offers 28 clinically actionable pharmacogenetic tests to help healthcare providers target treatment and medications to patient’s genetics. Studies have shown that incorporating genetic factors into the prescribing process can help improve efficacy and reduce adverse effects. Tests can be ordered as a panel, or individually.
All tests are powered by the YouScript Clinical Decision Support Tool.
RELIABILITY AND ACCURACY
An Experienced Lab
With more than 30 years of experience, we've pioneered a highly-complex laboratory which includes:
- Robotic DNA extraction and testing, to ensure high accuracy and low error
- Proprietary test platforms and methodologies
- Testing for more allele mutations than any other system
- Test validation across multiple platforms
- Ability to test non-invasive swab samples or blood
- Forensic-level protocols for sample accessioning
- Dedicated customer support
The Genelex testing laboratory is fully accredited and consistently maintains the highest standards. These standards include:
- College of American Pathologists (CAP) accreditation; 100% pass rate on CAP efficiency tests
- Clinical Laboratory Improvement Amendments (CLIA) certification; licensed to perform testing in all U.S. states
- State of New York Department of Health-accredited clinical laboratory for molecular genetic testing
- Agena Bioscience Certified Service Provider
- Secure Laboratory Information Systems (LIS)
- Code of Federal Regulations (CFR) 21 compliant
- Health Insurance Portability and Accountability Act (HIPAA) compliant
PGx TEST PANELS
The following is a list of test panels offered by Genelex. Your healthcare provider has the option to order individual genetic tests if he or she thinks it's necessary. If you have a question about what type of panel may be correct for you, please ask your provider or contact us.
(Includes major drug metabolizing enzymes) CYP2D6, CYP2C19, CYP2C9, CYP3A4, and CYP3A5
Polypharmacy Comprehensive Panel
(Includes additional psychotropic, analgesic, cardiology, oncology, infectious disease, rheumatology, gastroenterology, immunosuppression, anti-inflammatory, anticoagulant, hematology, urology, allergy, neurology, ADHD). CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP4F2, ADRA2A, COMT, CYP1A2, CYP2B6, DPYD (DPD), F2 (Factor II), F5 (Factor V) Leiden, MTHFR, GRIK4, HLA-B*57:01, HTR2A, HTR2C, IFNL3 (IL28B), NAT2, OPRM1, SLCO1B1, TPMT, VKORC1, UGT1A1
High Risk HLA Panel
HLA-A*31:01, HLA-B*15:02, HLA-B*57:01, HLA-B*58:01
PGx TESTING SPECIFICS
The Genelex Advantage
Our cutting-edge laboratories feature robotic DNA extraction, proprietary testing methodologies, and rapid turnaround times.
More than 85% of patients have significant genetic variations in the most important cytochromes  – CYP2D6, CYP2C9, CYP2C19, CYP3A4 and CYP3A5. For example, CYP3A4 and CYP3A5 affect the metabolism of one-half of the drugs in clinical use, and this variance is profoundly affected based on patient ethnicity. Additionally, Factor II Leiden (Factor 2 Leiden) and Factor V Leiden protein variations can increase the risk of dangerous cardiovascular events.
One variation example is CYP2D6. CYP2D6 acts on 25% of all prescription drugs. Approximately 7% of the population has a slow acting form of this enzyme and 7% a super-fast acting form. 35% are carriers of a non-functional CYP2D6 allele, which especially elevates the risk of ADEs when these individuals are taking multiple drugs. [6,33]
Drugs that CYP2D6 metabolizes include selective serotonin reuptake inhibitors (SSRI), tricylic antidepressants (TCA), beta-blockers, opiates, neuroleptics, antiarrhythmics, and a variety of toxic plant substances. Specific notable drugs include Prozac, Zoloft, Paxil, hydrocodone, Claritin, Haldol, Rythmol, tamoxifen, and Allegra. CYP2D6 is also responsible for activating the prodrugs codeine and other opioids into their active forms. The analgesic activity of the drugs is therefore reduced or absent in CYP2D6 poor metabolizers.